Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Aflibercept

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    145 result(s) found for: Aflibercept. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2018-002611-99 Sponsor Protocol Number: 20090 Start Date*: Information not available in EudraCT
    Sponsor Name:Bayer AG
    Full Title: Open-label, randomized, two–arm, controlled study to assess the efficacy, safety, and tolerability of intravitreal (IVT) aflibercept compared to laser photocoagulation in patients with retinopathy ...
    Medical condition: Retinopathy of prematurity
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10038933 Retinopathy of prematurity PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) NL (Completed) PT (Completed) GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) SK (Completed) AT (Completed) BG (Completed) PL (Completed) ES (Completed) HU (Completed) LT (Completed) EE (Completed) LV (Completed) GR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2014-001047-21 Sponsor Protocol Number: 690110 Start Date*: 2014-06-09
    Sponsor Name:Sankt Eriks Eye Hospital
    Full Title: Randomized trial comparing injection frequency between Aflibercept and Ranibizumab in patients with Central Retinal Vein Occlusion with a treat and extent algorithm
    Medical condition: Central retinal vein occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001208-12 Sponsor Protocol Number: 44122 Start Date*: 2013-08-30
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Switching to aflibercept in patients with neovascular AMD not responding to anti-VEGF treatment.
    Medical condition: Neovascular Age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003851-12 Sponsor Protocol Number: 20968 Start Date*: 2020-06-25
    Sponsor Name:Bayer AG
    Full Title: Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
    Medical condition: Neovascular Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing) LT (Ongoing) LV (Ongoing) PT (Ongoing) EE (Completed) AT (Ongoing) FR (Ongoing) SK (Ongoing) BG (Ongoing) CZ (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000103-27 Sponsor Protocol Number: Eylea-2014 Start Date*: 2014-03-12
    Sponsor Name:
    Full Title: Plasma levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept in patients with exudative age-related macular degeneration.
    Medical condition: Exudative age-related macular degeneration (AMD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000819-29 Sponsor Protocol Number: EFC10261 Start Date*: 2007-09-26
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Multinational, Randomized, Double-Blind Study Comparing Aflibercept Versus Placebo in Patients Treated with Second-Line Docetaxel after Failure of One Platinum Based Therapy for Locally Advanced ...
    Medical condition: Patients treated with second-line docetaxel after failure of one platinum based therapy for locally advanced or metastatic non-small-cell lung cancer (NSCLC).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GR (Completed) HU (Completed) IT (Completed) FR (Completed) AT (Prematurely Ended) EE (Completed) FI (Completed) SE (Completed) NL (Completed) BG (Completed) PT (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000690-73 Sponsor Protocol Number: BAY86-5321/21912 Start Date*: 2023-06-06
    Sponsor Name:Bayer AG
    Full Title: A Parallel-group Phase 4, Open-label, Two-arm Study to Assess the Safety and Efficacy of Intravitreal (IVT) Aflibercept with Proactive customized Treatment Intervals in Patients ≥50 Years of Age wi...
    Medical condition: Neovascular (wet) age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004756-20 Sponsor Protocol Number: EFC6546 Start Date*: 2007-09-19
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastat...
    Medical condition: Patients with metastatic androgen-independent prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) SE (Completed) CZ (Completed) PT (Completed) ES (Completed) DK (Completed) HU (Completed) EE (Completed) BE (Completed) NL (Completed) IT (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004464-54 Sponsor Protocol Number: BAY86-5321/16995 Start Date*: 2014-05-13
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-masked, sham-controlled phase 3b/4 study of the efficacy, safety, and tolerability of intravitreal aflibercept monotherapy compared to aflibercept with adjunctive photodynamic ...
    Medical condition: Polypoidal Choroidal Vasculopathy (PCV)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10015919 - Eye disorders 10063381 Polypoidal choroidal vasculopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003272-12 Sponsor Protocol Number: SIVS1012 Start Date*: 2014-04-08
    Sponsor Name:Moorfields Eye Hospital
    Full Title: Clinical Efficacy and Mechanistic Evaluation of Aflibercept for Proliferative Diabetic Retinopathy
    Medical condition: Proliferative Diabetic Retinopathy (PDR)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-004886-26 Sponsor Protocol Number: RTH258-C002 Start Date*: 2015-09-18
    Sponsor Name:Alcon Research Ltd
    Full Title: A Two-Year, Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RTH258 6mg Versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration
    Medical condition: Exudative senile macular degeneration of retina
    Disease: Version SOC Term Classification Code Term Level
    19.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) PT (Completed) FI (Completed) AT (Completed) NO (Completed) IE (Completed) ES (Completed) EE (Completed) LT (Completed) SE (Prematurely Ended) DE (Completed) HU (Completed) CZ (Completed) NL (Completed) GB (Completed) LV (Completed) DK (Completed) BE (Completed) PL (Completed) GR (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003643-30 Sponsor Protocol Number: VGFTe-HD-DME-1934 Start Date*: 2020-06-03
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients with Diabetic Macular Edema
    Medical condition: Diabetic Macular Edema
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004938-25 Sponsor Protocol Number: BAY86-5321/17613 Start Date*: 2016-07-07
    Sponsor Name:Bayer AG
    Full Title: An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of three different treatment regimens of 2 mg aflibercept administered by intr...
    Medical condition: Diabetic macular edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    19.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SK (Completed) HU (Completed) DE (Completed) AT (Completed) ES (Completed) CZ (Completed) LT (Completed) FR (Completed) PT (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001422-16 Sponsor Protocol Number: CT/14.01 Start Date*: 2015-10-13
    Sponsor Name:Hellenic Oncology Research Group
    Full Title: An open label, non-randomized, phase two trial in metastatic colorectal cancer (mCRC) with the combination of mFOLFIRI plus Aflibercept as first treatment: MINOAS trial
    Medical condition: Metastatic colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005449-18 Sponsor Protocol Number: MMT_2020_33 Start Date*: 2021-03-08
    Sponsor Name:Hôpital Fondation A. de Rothschild / Service de recherche clinique
    Full Title: Spontaneous retinal artery pulses as a prognostic determinant of central retinal vein occlusions in patients with and without intravitreal aflibercept injections.
    Medical condition: Central retinal vein occlusions
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001031-31 Sponsor Protocol Number: CRTH258BDE01 Start Date*: 2019-10-10
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A comperative BouBle Masked, Two-Arm, Randomized, MUlticenter, Phase IIb Study analyZing the Efficacy and Safety of BroluciZumab versus Aflibercept in Paients with Visual ImpaiRment due to Diabetic...
    Medical condition: diabetic macular edema
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000716-28 Sponsor Protocol Number: CRTH258A2303 Start Date*: 2019-09-02
    Sponsor Name:Novartis Pharma AG
    Full Title: A 64-week, two-arm, randomized, double-masked, multi-center, phase IIIb study assessing the efficacy and safety of brolucizumab 6 mg compared to aflibercept 2 mg in a treat-to-control regimen in pa...
    Medical condition: neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) IT (Ongoing) CZ (Completed) SE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) BE (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-000120-33 Sponsor Protocol Number: BAY86-5321/16598 Start Date*: 2015-08-26
    Sponsor Name:Bayer HealthCare AG
    Full Title: An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two differen...
    Medical condition: Neovascular Age-Related Macular Degeneration (nAMD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    18.1 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SK (Completed) PT (Completed) LT (Completed) AT (Completed) GB (GB - no longer in EU/EEA) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003476-19 Sponsor Protocol Number: EFC10547 Start Date*: 2007-11-21
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Multinational, Randomized, Double-Blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer.
    Medical condition: Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) HU (Completed) BE (Completed) FR (Completed) ES (Completed) AT (Completed) PL (Completed) IT (Prematurely Ended) BG (Completed) SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000820-42 Sponsor Protocol Number: EFC10262 Start Date*: 2008-06-24
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients with Metastatic Colorectal Cancer (MCRC) Treated with Irinotecan...
    Medical condition: Patients with metastatic colorectal cancer (MCRC) treated with irinotecan/5FU combination (FOLFIRI) after failure of an oxaliplatin based regimen.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GR (Completed) NL (Completed) CZ (Completed) EE (Completed) ES (Completed) DK (Completed) SE (Completed) BE (Completed) GB (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 05:30:27 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA